Peters J M, Hennuyer N, Staels B, Fruchart J C, Fievet C, Gonzalez F J, Auwerx J
Laboratory of Metabolism, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Biol Chem. 1997 Oct 24;272(43):27307-12. doi: 10.1074/jbc.272.43.27307.
The peroxisome proliferator-activated receptor-alpha (PPARalpha) controls gene expression in response to a diverse class of compounds collectively referred to as peroxisome proliferators. Whereas most known peroxisome proliferators are of exogenous origin and include hypolipidemic drugs and other industrial chemicals, several endogenous PPARalpha activators have been identified such as fatty acids and steroids. The latter finding and the fact that PPARalpha modulates target genes encoding enzymes involved in lipid metabolism suggest a role for PPARalpha in lipid metabolism. This was investigated in the PPARalpha-deficient mouse model. Basal levels of total serum cholesterol, high density lipoprotein cholesterol, hepatic apolipoprotein A-I mRNA, and serum apolipoprotein A-I in PPARalpha-deficient mice are significantly higher compared with wild-type controls. Treatment with the fibrate Wy 14,643 decreased apoA-I serum levels and hepatic mRNA levels in wild-type mice, whereas no effect was detected in the PPARalpha-deficient mice. Administration of the fibrate Wy 14,643 to wild-type mice results in marked depression of hepatic apolipoprotein C-III mRNA and serum triglycerides compared with untreated controls. In contrast, PPARalpha-deficient mice were unaffected by Wy 14,643 treatment. These studies demonstrate that PPARalpha modulates basal levels of serum cholesterol, in particular high density lipoprotein cholesterol, and establish that fibrate-induced modulation in hepatic apolipoprotein A-I, C-III mRNA, and serum triglycerides observed in wild-type mice is mediated by PPARalpha.
过氧化物酶体增殖物激活受体α(PPARα)可响应统称为过氧化物酶体增殖剂的多种化合物来控制基因表达。虽然大多数已知的过氧化物酶体增殖剂是外源性的,包括降血脂药物和其他工业化学品,但已鉴定出几种内源性PPARα激活剂,如脂肪酸和类固醇。后一发现以及PPARα调节参与脂质代谢的酶的编码靶基因这一事实表明PPARα在脂质代谢中发挥作用。这在PPARα缺陷小鼠模型中进行了研究。与野生型对照相比,PPARα缺陷小鼠的总血清胆固醇、高密度脂蛋白胆固醇、肝脏载脂蛋白A-I mRNA和血清载脂蛋白A-I的基础水平显著更高。用贝特类药物Wy 14,643处理可降低野生型小鼠的载脂蛋白A-I血清水平和肝脏mRNA水平,而在PPARα缺陷小鼠中未检测到影响。与未处理的对照相比,给野生型小鼠施用贝特类药物Wy 14,643会导致肝脏载脂蛋白C-III mRNA和血清甘油三酯显著降低。相反,PPARα缺陷小鼠不受Wy 14,643处理的影响。这些研究表明PPARα调节血清胆固醇的基础水平,特别是高密度脂蛋白胆固醇,并证实野生型小鼠中观察到的贝特类药物诱导的肝脏载脂蛋白A-I、C-III mRNA和血清甘油三酯的调节是由PPARα介导的。